UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/039,307	10/26/2001	Michael R.S. Hill	P-8969.00	2140
	27581 7590 01/26/2007 MEDTRONIC, INC.		EXAMINER	
710 MEDTRONIC PARK MINNEAPOLIS, MN 55432-9924		OROPEZA, FRANC	FRANCES P	
MINNEAI OLIS	5, IVIIN 33432-9924		ART UNIT	PAPER NUMBER
			3766	• .
SHORTENED STATUTORY	PERIOD OF RESPONSE	MAIL DATE	DELIVER	Y MODE
31 DA	AYS	01/26/2007	PAPER	

## Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

MI

	Application No.	Applicant(s)				
	10/039,307	HILL				
Office Action Summary	Examiner	Art Unit				
	Frances P. Oropeza	3766				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w.  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).  Status  1) Responsive to communication(s) filed on 11/19	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI date of this communication, even if timely filed	l. ely filed the mailing date of this communication. D (35 U.S.C. § 133).				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) ⊠ Claim(s) 1-40 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) 1-40 are subject to restriction and/or expressions.	vn from consideration.					
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the confidence of Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Examine 11.	epted or b) objected to by the Eddrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priori	s have been received. s have been received in Application ity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	te				

Art Unit: 3766

## **DETAILED ACTION**

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-16, drawn to a method comprising delivering cardiac pacing, and providing electrical stimulation to nervous tissue to improve the balance of a neuro-endocrinological system, classified in class 607, subclass 9.
  - II. Claims 17-27, drawn to an apparatus comprising a means for delivering cardiac pacing, and a means for automatically applying electrical stimulation to nervous tissue to improve the balance of a neuroendocrinological system based on a physiological signal, classified in class 607, subclass 9.
  - III. Claims 28-29, drawn to methods comprising delivering cardiac overdrive pacing or post-extra systolic potentiation therapy, and applying electrical stimulation to nervous tissue to balance/ improve the balance of a neuro-endocrinological system based on one of more psychological parameters, classified in class 607, subclass 9.
  - IV. Claims 30, drawn to an apparatus comprising a means for delivering overdrive cardiac pacing or post-extra systolic potentiation therapy, and a means for automatically applying and automatically adjusting electrical stimulation to nervous tissue to improve the balance of a neuro-endocrinological system based on one or more physiological parameters, classified in class 607, subclass 9.

Art Unit: 3766

- V. Claims 31, drawn to an apparatus comprising a means for delivering overdrive cardiac pacing or post-extra systolic potentiation therapy, and a means for automatically applying and automatically adjusting electrical stimulation to nervous tissue to alter the functioning of a heart based on one or more physiological parameters, classified in class 607, subclass 9.
- VI. Claims 32, drawn to an apparatus comprising a means for delivering cardiac overdrive pacing or post-extra systolic potentiation therapy, and a controller to automatically apply and automatically adjust electrical stimulation to nervous tissue associated with a neuro-endocrinological system based on one of more psychological parameters, classified in class 607, subclass 9.
- VII. Claims 33-40, drawn to an apparatus comprising a means for delivering cardiac overdrive pacing or post-extra systolic potentiation therapy, and a controller for applying electrical stimulation to nervous tissue to improve cardiac efficiency based on a psychological signal, classified in class 607, subclass 9.

The inventions are distinct, each from the other because of the following reasons:

Inventions I. and III. are different methods and are therefore individual and distinct.

Art Unit: 3766

Invention II. and inventions IV. V. and VI. are related as subcombinations disclosed as usable together in a single combination. The subcombinations are distinct if they do not overlap in scope and are not obvious variants, and if it is shown that at least one subcombination is separately usable. In the instant case, subcombination II. has separate utility such as an apparatus for improving cardiac performance not requiring the delivery of overdrive pacing of post-extra systolic potentiation therapy but rather providing pacing therapy. See MPEP § 806.05(d).

Invention IV. and invention V. are related as subcombinations disclosed as usable together in a single combination. The subcombinations are distinct if they do not overlap in scope and are not obvious variants, and if it is shown that at least one subcombination is separately usable. In the instant case, subcombination IV. has separate utility such as an apparatus for improving cardiac performance not requiring electrical stimulation to alter the heart, but rather applying electrical stimulation to improve balance of a neuroendocrinological system. See MPEP § 806.05(d).

Invention IV. and inventions VI. and VII. are related as subcombinations disclosed as usable together in a single combination. The subcombinations are distinct if they do not overlap in scope and are not obvious variants, and if it is shown that at least one subcombination is separately usable. In the instant case, subcombination IV. has separate utility such as an apparatus for improving cardiac performance not requiring a controller, but rather using a means for automatically applying and automatically adjusting the electrical stimulation to improve balance of a neuro-endocrinological system. See MPEP § 806.05(d).

Art Unit: 3766

Invention V. and inventions VI. and VII. are related as subcombinations disclosed as usable together in a single combination. The subcombinations are distinct if they do not overlap in scope and are not obvious variants, and if it is shown that at least one subcombination is separately usable. In the instant case, subcombination V. has separate utility such as an apparatus for improving cardiac performance not requiring a controller, but rather using a means for automatically applying and automatically adjusting the electrical stimulation to alter the functioning of the heart. See MPEP § 806.05(d).

Invention VI. and invention VII. are related as subcombinations disclosed as usable together in a single combination. The subcombinations are distinct if they do not overlap in scope and are not obvious variants, and if it is shown that at least one subcombination is separately usable. In the instant case, subcombination VI. has separate utility such as and apparatus for improving cardiac performance not by stimulating non-specific neural tissue, but rather by stimulating a nervous tissue associated with a neuro-endocrinological system. See MPEP § 806.05(d).

The examiner has required restriction between subcombinations usable together. Where applicant elects a subcombination and claims thereto are subsequently found allowable, any claim(s) depending from or otherwise requiring all the limitations of the allowable subcombination will be examined for patentability in accordance with 37 CFR 1.104. See MPEP § 821.04(a). Applicant is advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to

Art Unit: 3766

provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

The Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143

The Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Fran Oropeza whose telephone number is (571) 272-4953. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert E. Pezzuto can be reached on (571) 272-6996. The fax phone numbers for the organization where this application or proceeding is assigned is (571) 273-8300 for regular communication and for After Final communications.

Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 3766

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business

Frances P. Oropeza Patent Examiner Art Unit 3766 JY0 1-21-07

Robert E. Pezzuto
Supervisory Patent Examiner

Page 7

Art Unit 3766